Revolution Medicines, a clinical oncology company focused on RAS-addicted cancers, will announce its financial results for the second quarter of 2026 on August 5 after market close. The company's senior management will host a webcast at 4:30 p.m. ET to discuss the results and provide updates on corporate progress. Revolution Medicines is developing targeted therapies including several RAS(ON) inhibitors currently in clinical trials, aiming to address various oncogenic RAS mutations. Investors can access the live webcast or replay on the company's website.
The Vanguard Morningstar Mega Cap Value ETF (MGV) has been downgraded to a hold rating due to weakening technical momentum, even though its valuation metrics remain strong with a modest price-to-earnings ratio of 16.8 and a PEG ratio below 1.5. The E...
Palo Alto Networks is gaining from increased focus on AI safety and potential regulatory pauses in AI development, as enterprises shift spending toward secure cloud infrastructure. The company reported a 34% year-over-year revenue growth in Q4 2026 a...
Oil prices fell on Monday as traders monitored the steady flow of Middle East oil despite recent attacks on Saudi Arabia's East-West pipeline by Iran-backed Houthis. Brent crude dropped 1.66% to $102.15 per barrel, and US West Texas Intermediate fell...
CashCat's price fell about 30% in 24 hours due to broader crypto market weakness, breaking a key resistance but reaching a support level within a bullish channel. Indicators show bears currently dominate, yet rising Money Flow Index and positive Fund...
Solidion Technology has combined the roles of Chairman and CEO, appointing Jaymes Winters to lead both positions to strengthen governance and strategic execution. Winters brings over 15 years of CEO experience across various industries and will focus...
